GERON CORP (GERN)       2.29  +0.07 (+3.15%)

2.29  +0.07 (+3.15%)

US3741631036 - Common Stock - After market: 2.28 -0.01 (-0.44%)


Fundamental Rating

2

Overall GERN gets a fundamental rating of 2 out of 10. We evaluated GERN against 631 industry peers in the Biotechnology industry. GERN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, GERN is valued expensive at the moment.




Profitability

Profitability Rating

0

GERN has negative profitability rations, so we won't be analyzing them here.
GERN's Return On Assets of -56.44% is worse than the rest of the industry. The industry average Return On Assets is -44.51%.

GERN's Profit Margin of -8563.80% is worse than the rest of the industry. The industry average Profit Margin is -464.10%. 89% of the industry peers have a better Profit Margin.
The Piotroski-F score of GERN is 2.00. This is a very weak score and indicates problems in health and profitability for GERN.
VS Industry

ROA (-56.44%) VS Industry: 37% outperformed.

-950.38
52.28

Profit Margin (-8563.8%) VS Industry: 11% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

1

With a price book ratio of 8.07, GERN is valued correctly.
GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
When comparing the price book ratio of GERN to the average industry price book ratio of 1.67, GERN is valued more expensive than its industry peers. 92% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (8.07) VS Industry: 8% outperformed.

130.23
0.10

Growth

Growth Rating

6

The Revenue has grown by 277.59% in the past year. This is a very strong growth!
Based on estimates for the next 5 years, GERN will show a very strong growth in Revenue. The Revenue will grow by 813.01% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

GERN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.09%.
Based on estimates for the next 5 years, GERN will show a small growth in Earnings Per Share. The EPS will grow by 3.36% on average per year.
The Revenue for GERN have been decreasing by -25.72% on average. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -9.09% -8.23% -12.92% 11.62% 3.36%
Revenue-25.72% 9.19% 277.59% -10.99% 117.99% 531.8% 813.01%

Health

Health Rating

2

A Current Ratio of 2.68 indicates that GERN has no problem at all paying its short term obligations.
GERN has a Quick Ratio of 2.68. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.18, GERN is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, GERN is worse placed to pay its short term obligations than its industry peers.

GERN has one of the worst Debt to Equity ratios in its industry. 87% of its industry peers require less debt for financing their operations.
Based on the Altman-Z score of -5.26, we must say that GERN is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.76, GERN is in worse financial health than its industry peers.
The Piotroski-F score of GERN is 2.00. This is a very weak score and indicates problems in health and profitability for GERN.
VS Industry

Debt/Equity (0.35) VS Industry: 13% outperformed.

15.37
0.00

Quick Ratio (2.68) VS Industry: 23% outperformed.

0.02
84.53

Current Ratio (2.68) VS Industry: 22% outperformed.

0.02
85.09

Altman-Z (-5.26) VS Industry: 27% outperformed.

-135.10
484.91

Dividend

Dividend Rating

0

No dividends for GERN!.

GERN Daily chart

GERON CORP2.29

NASDAQ:GERN (11/28/2022, 7:00:01 PM)+0.07 (+3.15%)

After market: 2.28 -0.01 (-0.44%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 03-08 2023-03-08
Ins Owners 0.13% Inst Owners 49.56%
Market Cap 873.03M Analysts 86.67
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 569.49 P/B 8.07
EV/EBITDA -4.47
Dividend
Dividend Yield N/A Dividend Growth N/A
DP 0% Ex-Date N/A
Growth
EPS 1Y -9.09% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -25%
EPS Next Y -8.23% EPS Next 2Y -12.92%
EPS Next 3Y 11.62% EPS Next 5Y 3.36%
Revenue growth 1Y 277.59% Revenue growth 3Y 9.19%
Revenue growth 5Y -25.72% Revenue growth Q2Q 172.48%
Revenue Next Year -10.99% Revenue Next 2Y 117.99%
Revenue Next 3Y 531.8% Revenue Next 5Y 813.01%
Health
Current Ratio 2.68 Quick Ratio 2.68
Altman-Z -5.26 F-Score 2
Debt/Equity 0.35 WACC 9.21%
ROIC/WACC N/A
Profitability
ROA -56.44% ROE N/A
ROICexgc N/A ROIC N/A
PM -8563.8% OM -8322.31%
Asset Turnover 0.01

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA